Physician profile
Kyle Blair
NPI 1881071348
$1,480.14
in general payments reported to CMS, 2019-2025
24 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $198 · 2021: $36.37 · 2022: $56.66 · 2024: $23.59 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $241.31 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $210.88 | 2019-2025 | Shingrix, Arexvy |
| Pfizer INC. | $193.71 | 2019-2025 | |
| Abbvie INC. | $164.93 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $87.70 | 2019-2024 | Breztri |
| Novo Nordisk INC | $59.90 | 2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.90 | 2019 | |
| Genentech USA, INC. | $51.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.88 | 2019-2020 | |
| Allergan, INC. | $42.63 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.39 | 2019-2020 | |
| Horizon Therapeutics Plc | $35.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.51 | 2019-2025 | Jardiance |
| Supernus Pharmaceuticals, INC. | $26.66 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.91 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.64 | 2019 | |
| Inspire Medical Systems, INC. | $23.03 | 2025 | Inspire |
| Dexcom, INC. | $22.26 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.22 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $15.60 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.02 | 2020 | |
| Grifols USA, LLC | $13.77 | 2019 | |
| Amarin Pharma, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.